CD274 and cancer: Despite the profound local inflammation reaction and excellent antitumor therapeutic efficacy, we observed extremely low systemic toxicity induced by the BNT162b2-based cancer therapy and the combinational therapy of BNT162b2 and anti-PD-L1.